Plasma and whole-body turnover studies of human C-reactive protein (CRP), isolated from a single normal healthy donor and labeled with 125I, were undertaken in 8 healthy control subjects and 35 hospitalized patients including cases ofrheumatoid arthritis, systemic lupus erythematosus, infections, and neoplasia. Plasma clearance of '25I-CRP closely approximated to a monoexponential function and was similar in the control and all patient groups. There was no evidence for accelerated clearance or catabolism of CRP in any of the diseases studied. The 19-h half-life was more rapid than that of most human plasma proteins studied previously, and the fractional catabolic rate was independent of the plasma CRP concentration. The synthesis rate of CRP is thus the only significant determinant of its plasma level, confirming the validity of serum CRP measurement as an objective index of disease activity in disorders associated with an acute-phase response. Approximately 90% of injected radioactivity was recovered in the urine after 7 d, and scintigraphic imaging studies with 13I-labeled CRP in 10 patients with different focal pathology showed no significant localization of tracer. The functions of CRP are thus likely to be effected predominantly in the fluid phase rather than by major deposition at sites of tissue damage or inflammation. (J. Clin. Invest. 1993. 90:1351-1357 Key words: C-reactive protein.
component (SAP), CRP is a member of the pentraxin family of proteins which are unrelated to other known proteins, but which are themselves stably conserved in vertebrate evolution (2) . No polymorphism ofeither the gene coding sequence or of the protein itself has been described in man, nor has any individual lacking CRP been identified, suggesting that CRP has an important biological role. This may be related to specific binding of CRP to phosphocholine-containing molecules including plasma lipoproteins, cell membrane phospholipids, microbial products and phospholipid mediators, such as platelet-activating factor (PAF) (3, 4) . Contrary to some reports (5, 6) , human CRP does not bind to chromatin under physiological conditions (7, 8) but it does bind avidly and specifically to small nuclear ribonucleoprotein particles within whole nuclei (9) .
Binding of CRP to soluble and particulate ligands can opsonise them for phagocytosis, predominantly via the classical complement pathway which complexed or aggregated CRP activates with high efficiency (10, 11) . There is also some evidence for the existence of receptors for CRP on the surface of polymorphs and monocyte/macrophages, and it has been claimed that CRP and/or its fragments have functional activity in modifying the behaviour ofthese cells ( 1 1-14) . Heterologous, human, CRP protects mice against pneumococcal infection ( 15, 16) but there is no evidence for a similar protective role of autologous CRP, for example, in the human or the rat (3), or for human CRP in mice with other infections. Thus, although the many different properties of CRP which have been described suggest that it may contribute to lipid metabolism, scavenging and repair of damaged cells and tissues, host defence against infection and modulation of inflammation, no definite in vivo functions of CRP have yet been identified.
In normal healthy subjects CRP is a trace plasma protein with a median level of 0.8 mg/liter (17) . It is produced by hepatocytes in which its synthesis is regulated by cytokines, particularly IL-6 (18) . CRP levels rise rapidly and dramatically in response to bacterial infection, trauma, tissue necrosis, and most forms of inflammation, and may exceed 300 mg/liter within 48 h of an acute event ( 1, 2) . High levels may persist indefinitely in chronic inflammatory states. In contrast, there are a few important disorders, particularly systemic lupus erythematosus (SLE) and related collagen diseases, ulcerative colitis, and leukemia, in which CRP levels usually remain normal, or are only modestly elevated, even in the presence of severe tissue damaging pathology ( 1, 2) . The mechanisms underlying this phenomenon are not known, though affected individuals retain the capacity to develop a typical major acute phase reaction in response to intercurrent microbial infection or tissue infarction ( 1, 2).
The isolation of pure CRP from the plasma of a single normal healthy individual, which we report here, has enabled us to study the in vivo distribution and metabolism of human CRP in health and in various diseases, including rheumatoid arthritis (RA), SLE, bacterial infection, and neoplasia.
Methods
Isolation of CRP. Highly purified human CRP was prepared by calcium-dependent affinity chromatography, reverse affinity chromatography and gel filtration ( 19, 20) , from 10 (23, 24) including the amino-terminal pyrrolidone carboxylic acid residue (25 Turnover study protocol. After excluding a history of adverse reactions to iodide, thyroid uptake of radioiodine was blocked by the prior administration of oral potassium iodide. 180 kBq of '25I-CRP was administered by bolus intravenous injection, resulting in an effective dose equivalent of 0.045 mSv. Venous blood samples were drawn from the contralateral forearm at 10-min intervals for the first 30 min, hourly for the following 6 h and then daily for 7 d. Consecutive 24-h urine collections were obtained for the study period. Protein bound radioactivity in 0.5-ml aliquots of all serum samples, and total radioactivity in 1-ml aliquots of each 24-h urine collection were counted simultaneously with a standard aliquot of the injected material. The results were expressed as a percentage of the injected quantity per liter of serum or urine. In one normal subject and two patients with raised plasma CRP levels each whole blood sample, its clot and serum sample were counted separately in order to assess uptake oftracer by blood cells; no such uptake was detected. The total CRP concentration was measured by electroimmunoassay (28) and when necessary by immunoradiometric assay (29) in all serum samples, and all the subjects reported here had constant values throughout the period of study. Other individuals in whom serum CRP concentrations varied have been excluded from this report.
Curvefitting and metabolic analysis. Plasma activity data were fitted to a single exponential function by non-linear regression. Plasma volumes were estimated from body surface area, and calculated from the y-axis intersect at notional time zero. The synthesis rate for CRP was derived from the area under the curve and its biological half-life and fractional clearance rate from the value of the exponent. The whole-body retention of radioactivity was calculated at daily intervals by subtracting the cumulative activity excreted in the urine from the total injected radioactivity. Statistical significance of differences between CRP metabolism in normal controls and disease groups was sought by one way analysis of variance.
'23I-CRP scintigraphic imaging studies. For imaging and localization studies CRP was labeled with '231, a medium energy pure gamma emitter, which has a short half-life of 13.2 h and is ideally suited to in vivo scintigraphic imaging (27, 30) . After thyroid blockade, each subject received 200 MBq of '23I-CRP by bolus intravenous injection, resulting in an effective dose equivalent of 4 mSv, comparable to that of an intravenous pyelogram or barium series. Anterior and posterior whole body scintigraphic imaging were performed immediately after injection and at 6, 24, and 48 h using the IGE-Starcam gamma camera (IGE Medical Systems, Slough, UK) with a medium energy parallel hole collimator. Regional views and quantitative analysis oftracer localization to liver, spleen, kidneys and other sites of interest were performed. Three female and 7 male patients, aged 26-84 yr, were studied. Four patients had malignant neoplasms: metastatic bronchogenic carcinoma (two patients), multiple myeloma and systemic AL amyloidosis (one), and retroperitoneal T cell lymphoma (one). Three patients had local infections, respectively: thoracic vertebral osteomyelitis, pneumococcal lobar pneumonia, and post-operative psoas abscess. Three patients had active idiopathic inflammatory diseases, respectively: Crohn's disease of the terminal ileum complicated by systemic AA amyloidosis, polymyositis, and SLE complicated by an intercurrent acute infective pharyngitis.
Ethical approval. All participants gave informed written consent and the project was approved by the Research Ethics Committee of Hammersmith Hospital and the Administration of Radioactive Substances Advisory Committee of the Department of Health, United Kingdom.
Results
Clearance of iodinated CRP in vivo in animals. The in vivo plasma clearance of 125I-CRP in mouse and rabbit was indistinguishable from that of isolated unlabeled CRP, or of CRP provided in whole acute phase serum. In mice the tl2 was 4 h and in the rabbit it was 7 h, values similar to those previously reported (31) (32) (33) . Together with the precise mass spectrometric confirmation of the structure of the subunits of the single donor CRP and the in vitro biochemical evidence for full structural and ligand-binding integrity of the labeled CRP, these observations establish the validity of the present preparations as in vivo tracers of CRP metabolism.
Clearance of'25I-CRP in normal volunteers. In normal subjects there was an initial distribution phase lasting several hours during which plasma activity fell relatively rapidly. This was followed by a slower steady decline throughout the 7-d study period during which the mean (SD) plasma half-life was 18.8 (3.9) h. Plasma clearance was paralleled by whole body radioactivity with a delay of 24 h, indicating that substantial tissue sequestration of '25I-CRP did not occur (Fig. 1) . At 7 d the whole-body clearance was mean (SD) 88 (6.9%) ofthe injected dose. Plasma 251I-CRP activity values closely approximated to a monoexponential function in all subjects. Total plasma CRP levels remained constant throughout the period of study (median 0.8 mg/liter) enabling various metabolic parameters to be calculated. The fractional clearance rate ofCRP was 92% ofthe plasma pool per day, and equal to the fractional catabolic rate measured directly from the cumulative urinary excretion of 1251. The synthesis rate of CRP was -2.4 mg/24 h and the calculated notional time zero volume ofdistribution was -1.4 times greater than the plasma volume estimated from body surface area, consistent with the expected behaviour ofa molecule of mass 115,135 D, and indicating that CRP is predominantly intravascular.
Clearance and metabolic analysis of '25I-CRP in patients with inflammatory and noninflammatory disease. In 5 patients with active RA, who had a median circulating CRP concentration of 59 mg/liter (range 13-152), the plasma turnover of '251-CRP did not differ significantly from normal healthy volunteers (Fig. 2) . The turnover was also normal in one patient with inactive RA (Table I) remained constant in two cases who were restudied after successful treatment and normalization of CRP levels (not shown). In active SLE uncomplicated by infection the circulating CRP concentration is often within normal limits and is rarely more than modestly elevated (34) . It was therefore of particular interest that plasma clearance of 1251-CRP was normal, both in five patients with active disease and no elevation of CRP level (Fig. 2 ) and in one patient with an intercurrent bacterial infection and a plasma CRP concentration of 56 mg/ liter (Table I ). The volume of distribution for the tracer was not increased in any of the patients, excluding first pass extravascular localization. This constancy of CRP turnover was confirmed in four patients with, respectively, active polymyositis, active SLE overlap syndrome, inactive polyarteritis and Crohn's disease with AA amyloidosis and in five individuals with malignant neoplasia (Table I ). The fractional catabolic rate of CRP was thus independent of the plasma CRP concentration, whilst there was a direct linear relationship between plasma levels and the calculated rate of CRP production (Fig. 3) . This rate is evidently greatly increased during the acute phase response and may exceed 360 mg/24 h. '23I-CRP scintigraphy. Scintigraphs were obtained after the intravenous injection of '23I-CRP in 10 patients with diseases in which inflammation and tissue damage were prominent, including a patient with active polymyositis and normal CRP and one with active SLE and a raised CRP (58 mg/ml), possibly related to intercurrent infective pharyngitis. In all these subjects the distribution of tracer activity was confined to the blood pool and no selective tissue or organ localization could be identified (Fig. 4) . Despite the administration of potassium iodide, minor uptake of radioactivity was occasionally seen in the salivary glands, thyroid, and stomach. This nonspecific localization reflects the known distribution of free radioiodine, and quantitatively represented < 1% of the injected radioactivity.
Discussion
These studies are the first to describe the in vivo turnover and distribution of human CRP in man in health and disease. The CRP used, unlike that in all previous reported work on human CRP, was isolated from the serum of a single normal healthy donor. This was essential, on ethical grounds, to avoid any risk oftransmissible disease. The radioiodinated protein retained in full its normal structure and ligand-binding properties in vitro. Furthermore, the labeled CRP was handled in vivo in laboratory animals in a manner identical to purified human CRP which had not been labeled, and to completely untreated CRP administered by injection of whole acute phase human serum.
In that there is no evidence for polymorphism ofeither the gene coding sequence for human CRP or the protein itself, the behavior of the labeled isologous tracer can be confidently taken to reflect that of autologous CRP in the body. In normal subjects clearance of CRP from the plasma was monoexponential with a biological half-time of 19 h, indicating extremely rapid turnover compared with the majority of plasma proteins. This finding is consistent with previous observations that elevated circulating levels ofCRP fall by up to 50% per day when the acute-phase stimulus resolves (35) . In several individuals 100% of the injected radioactivity was recovered in the urine after 7 d indicating that there was no localization and/or sequestration ofthe labeled protein. Slightly lower rates of recovery in other subjects probably reflect minor loss of radioactivity via the gastrointestinal tract, which accounts for up to 5% in turnover studies of other radioiodinated plasma proteins. In the one normal and two patients in whom it was sought there was no uptake/binding to blood cells. Analysis of the single compartment model used here suggests that -30% of CRP is extravascular, though in free equilibrium with the plasma pool, and is consistent with the expected behavior of a molecule of mass 115,135 D.
Amongst patients studied with a variety of inflammatory and neoplastic conditions, resulting in elevated levels of circu- There is no signal from the site of the lesion. Right: Posterior image at 6 h of a patient with myeloma and extensive hepatic and renal AL amyloidosis who had previously undergone splenectomy. Tracer is distributed in the blood pool only.
lating CRP and in whom there was likely to be an abundance of the putative ligands with which CRP might interact, there were no differences in the turnover and clearance of 1251I-CRP. Re- sults for the plasma half-life, fractional catabolic rate directly measured from the urinary excretion of radioactivity, and whole-body retention of radioactivity after 7 d were identical to normal controls, indicating that there was no substantial sequestration or altered handling of CRP in these disease states.
In two patients with infections, who were studied both during the acute phase of the illness and subsequently when serum CRP levels had normalized, identical turnover profiles were obtained. Similarly, no differences were observed in patients with active SLE and polymyositis, in whom characteristically normal circulating levels of CRP were present. (31) . CRP clearance was also unaffected by the intravascular presence of even macromolecular ligands to which CRP binds, such as apoB-containing lipoproteins (in the rabbit) or pneumococcal C-polysaccharide (32, 33) . Formation of CRP-ligand complexes in the circulation thus does not accelerate CRP clearance, which apparently proceeds under all circumstances at a constant maximum rate via a mechanism which is apparently not saturable. This does not preclude the possibility that CRP binding may modulate the rate and/or site ofclearance ofligands compared with their fate in the absence of CRP. Indeed human CRP passively administered to mice alters in favour of the spleen the balance of splenic and hepatic uptake of pneumococci, of C-polysaccharide-coated mouse erythrocytes and of free C-polysaccharide, although the overall blood clearance rate of these ligands is not affected (3, 33, 37, 38 (48, 49) or essential controls for immunological specificity omitted (48) . Significant CRP is present only rarely at sites of inflammation per se, although it definitely does appear in small amounts on frankly necrotic muscle fibres in cardiac or skeletal muscle damaged by extreme experimental procedures (3, 43, 44, 50) . The present failure to detect significant tissue deposition of 1231I-CRP in any of the various pathologies studied is therefore compatible with the paucity of convincing immunohistochemical evidence, but we cannot exclude the possibility that avid binding of autologous CRP to potential tissue ligands at an early stage ofdisease may have blocked their subsequent availability for interaction with the tracer.
Among previous speculations about the function of CRP, the results reported here are most consistent with the original suggestion of Pepys (1) that CRP acts to bind and thereby neutralize or "detoxify" harmful substances which gain access to the circulation. Such substances may be of extrinsic, microbial origin, like C-polysaccharide and related materials, which are widely distributed in nature, or of autologous origin. For example, CRP efficiently blocks the biological activity of the potent phosphocholine-containing inflammatory mediator, PAF (4, 51, 52) . CRP also binds to lysophospholipids (53) and may prevent their damaging effects (4, 51, 52). Furthermore, CRP may block the phospholipase activities which provide substrates for the cyclo and lipooxygenase pathways (4). Interesting preliminary data from mice transgenic for rabbit CRP show that the presence of this xenogeneic CRP, in a species which produces very little of its own CRP, efficiently protects the animals from endotoxin lethality and that the mechanism of this protection is largely via inactivation of PAF (54, 55) . A major role of CRP may therefore be to bind and neutralize PAF and other biologically active phospholipid ligands in plasma and tissue fluids. Raised concentrations of CRP are present in conditions likely to be associated with increased production and/or release of such mediators and may thereby serve to control their effects. The rabbit CRP transgenic mice are also apparently protected against GSa-induced alveolitis (56) , and a further role of CRP and/or its fragments in modulating chemotaxis and activity ofneutrophils ( 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] would be compatible with the present findings of unvarying clearance and lack of tissue deposition of CRP in humans.
